$3.05
+0.16
(+5.54%)▲
5.9%
Downside
Day's Volatility :8.01%
Upside
2.24%
29.51%
Downside
52 Weeks Volatility :58.09%
Upside
40.55%
Period | Anixa Biosciences, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -10.53% | 6.5% | 0.0% |
6 Months | -34.02% | 7.1% | 0.0% |
1 Year | -18.59% | 9.8% | 0.0% |
3 Years | -33.56% | 14.2% | -20.2% |
Market Capitalization | 92.5M |
Book Value | $0.74 |
Earnings Per Share (EPS) | -0.37 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -31.21% |
Return On Equity TTM | -48.41% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 127.5K |
EBITDA | -13.1M |
Diluted Eps TTM | -0.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.43 |
EPS Estimate Next Year | -0.45 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 129.51%
Sell
Neutral
Buy
Anixa Biosciences, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Anixa Biosciences, Inc. | 21.94% | -34.02% | -18.59% | -33.56% | -38.51% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Anixa Biosciences, Inc. | NA | NA | NA | -0.43 | -0.48 | -0.31 | NA | 0.74 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Anixa Biosciences, Inc. | Buy | $92.5M | -38.51% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Anixa Biosciences, Inc.
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 80.2%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 220.1%
Vanguard Group Inc
Laird Norton Tyee Trust Co
UBS Group AG
Mission Wealth Management, LLC
Susquehanna International Group, LLP
Geode Capital Management, LLC
itus develops and acquires patented technologies for the purposes of patent monetization and patent assertion. the company currently has 8 patent portfolios in the areas of key based web conferencing encryption, encrypted cellular communications, nano field emission display (“nfed”), micro electro mechanical systems display (“mems”), j-channel window frame construction, vpn multicast communications, internet telephonic gateway, and enhanced auction technologies. itus’s management team has over 30 years of combined experience in patent monetization and patent assertion, and has generated in excess of $150 million patent licensing revenues
Organization | Anixa Biosciences, Inc. |
Employees | 4 |
CEO | Dr. Amit Kumar Ph.D. |
Industry | Electronic Technology |
A Spac I Acquisition Corp
$3.05
+5.54%
Keyarch Acquisition Corp
$3.05
+5.54%
Connexa Sports Technologies Inc
$3.05
+5.54%
Us Value Etf
$3.05
+5.54%
First Wave Biopharma Inc
$3.05
+5.54%
Global X Msci Next Emerging
$3.05
+5.54%
Fat Projects Acquisition Corp
$3.05
+5.54%
Capital Link Global Fintech
$3.05
+5.54%
Applied Uv Inc
$3.05
+5.54%